**SB 98, TREATMENT MEDICATION AMENDMENTS, (Mayne, K)**

**Anticipated Fiscal Impact:**

$0 per year ($0 PEPM)

**Summary:**

SB 98 limits the ability of PEHP to require step therapy prior to coverage for medicines in cases where: 1) the drugs are on PEHP’s formulary; 2) the drugs are approved and indicated for stage IV metastatic cancer by either the FDA or NCCN; and 3) the drugs are supported by peer reviewed literature. This bill limits step therapy to two steps for these drugs and eliminates step therapy if the drug is the only FDA approved drug for the condition on the market. However, PEHP and other plans are not required to cover drugs not on the formulary or limit the use of biosimilar drugs. Currently, PEHP does not have any drugs on the formulary where step-therapy would have to be modified to comply with the provisions of this bill. Consequently, there is no immediate fiscal impact of this bill on the state. It is possible, however, that with new, expensive medications coming to market to treat stage IV metastatic cancer, this bill could limit future actions of PEHP with respect to those drugs and thereby increase costs to the state. It is not possible to estimate such costs, but the potential exists.